Gillian M Air

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/346636/publications.pdf

Version: 2024-02-01

92	6,094	71061 41	71651 76
papers	citations	h-index	g-index

94	94	94	6040
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Novel isoforms of influenza virus PA-X and PB1-F2 indicated by automatic annotation. Virus Research, 2021, 304, 198545.	1.1	1
2	Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence. Scientific Reports, 2016, 6, 36216.	1.6	43
3	Possible basis for the emergence of H1N1 viruses with pandemic potential from avian hosts. Emerging Microbes and Infections, 2015, 4, 1-10.	3.0	14
4	Influenza virus antigenicity and broadly neutralizing epitopes. Current Opinion in Virology, 2015, 11, 113-121.	2.6	29
5	Editorial overview: virusâ€“glycan interactions and pathogenesis. Current Opinion in Virology, 2014, 7, v-vi.	2.6	0
6	Glycan array analysis of influenza H1N1 binding and release. Cancer Biomarkers, 2014, 14, 43-53.	0.8	31
7	Glycomic Characterization of Respiratory Tract Tissues of Ferrets. Journal of Biological Chemistry, 2014, 289, 28489-28504.	1.6	82
8	Influenza virusâ€“glycan interactions. Current Opinion in Virology, 2014, 7, 128-133.	2.6	38
9	Glycomic Analysis of Human Respiratory Tract Tissues and Correlation with Influenza Virus Infection. PLoS Pathogens, 2013, 9, e1003223.	2.1	209
10	Quantitative Comparison of Human Parainfluenza Virus Hemagglutinin-Neuraminidase Receptor Binding and Receptor Cleavage. Journal of Virology, 2013, 87, 8962-8970.	1.5	19
11	Human H3N2 Influenza Viruses Isolated from 1968 To 2012 Show Varying Preference for Receptor Substructures with No Apparent Consequences for Disease or Spread. PLoS ONE, 2013, 8, e66325.	1.1	101
12	Influenza Virus Sequence Feature Variant Type Analysis: Evidence of a Role for NS1 in Influenza Virus Host Range Restriction. Journal of Virology, 2012, 86, 5857-5866.	1.5	35
13	Functional Glycomic Analysis of Human Milk Glycans Reveals the Presence of Virus Receptors and Embryonic Stem Cell Biomarkers. Journal of Biological Chemistry, 2012, 287, 44784-44799.	1.6	90
14	Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: The hydrophobic side chain influences type A subtype selectivity. Bioorganic and Medicinal Chemistry, 2012, 20, 4582-4589.	1.4	14
15	Crystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6. BMC Structural Biology, 2012, 12, 7.	2.3	11
16	Immunodominance of Antigenic Site B over Site A of Hemagglutinin of Recent H3N2 Influenza Viruses. PLoS ONE, 2012, 7, e41895.	1.1	92
17	Evaluations for In Vitro Correlates of Immunogenicity of Inactivated Influenza A H5, H7 and H9 Vaccines in Humans. PLoS ONE, 2012, 7, e50830.	1.1	44
18	Influenza neuraminidase. Influenza and Other Respiratory Viruses, 2012, 6, 245-256.	1.5	202

#	Article	IF	Citations
19	Probing Virusâ€“Glycan Interactions Using Glycan Microarrays. Methods in Molecular Biology, 2012, 808, 251-267.	0.4	25
20	Individual Antibody and T Cell Responses to Vaccination and Infection with the 2009 Pandemic Swine-Origin H1N1 Influenza Virus. Journal of Clinical Immunology, 2011, 31, 900-912.	2.0	7
21	The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles. Retrovirology, 2011, 8, 101.	0.9	63
22	Influenza vaccination responses in human systemic lupus erythematosus: Impact of clinical and demographic features. Arthritis and Rheumatism, 2011, 63, 2396-2406.	6.7	63
23	A Sialylated Glycan Microarray Reveals Novel Interactions of Modified Sialic Acids with Proteins and Viruses. Journal of Biological Chemistry, 2011, 286, 31610-31622.	1.6	125
24	Fixation of Oligosaccharides to a Surface May Increase the Susceptibility to Human Parainfluenza Virus 1, 2, or 3 Hemagglutinin-Neuraminidase. Journal of Virology, 2011, 85, 12146-12159.	1.5	21
25	HLA class I molecules consistently present internal influenza epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 540-545.	3.3	61
26	Antibody quantity versus quality after influenza vaccination. Vaccine, 2009, 27, 6358-6362.	1.7	50
27	Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses. Virology Journal, 2009, 6, 22.	1.4	34
28	Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature, 2008, 453, 667-671.	13.7	959
29	Evolving complexities of influenza virus and its receptors. Trends in Microbiology, 2008, 16, 149-157.	3.5	185
30	Variability in HLA class I viral peptide presentation during infection with two different Influenza A H1N1 strains. FASEB Journal, 2008, 22, 1068.2.	0.2	0
31	Human Parainfluenza Viruses hPIV1 and hPIV3 Bind Oligosaccharides with Î±2-3-Linked Sialic Acids That Are Distinct from Those Bound by H5 Avian Influenza Virus Hemagglutinin. Journal of Virology, 2007, 81, 8341-8345.	1.5	63
32	Receptor binding specificity of recent human H3N2 influenza viruses. Virology Journal, 2007, 4, 42.	1.4	146
33	Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination. Influenza and Other Respiratory Viruses, 2007, 1, 147-156.	1.5	14
34	An Epidemiologically Significant Epitope of a 1998 Human Influenza Virus Neuraminidase Forms a Highly Hydrated Interface in the NAâ€“Antibody Complex. Journal of Molecular Biology, 2006, 356, 651-663.	2.0	57
35	Interaction between a 1998 human influenza virus N2 neuraminidase and monoclonal antibody Mem5. Virology, 2006, 345, 424-433.	1.1	14
36	Mismatched hemagglutinin and neuraminidase specificities in recent human H3N2 influenza viruses. Virology, 2005, 339, 12-20.	1.1	45

#	Article	IF	Citations
37	Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine, 2005, 23, 1414-1425.	1.7	51
38	Binding of influenza viruses to sialic acids: reassortant viruses with A/NWS/33 hemagglutinin bind to Î±2,8-linked sialic acid. Virology, 2004, 325, 340-350.	1.1	39
39	A benzoic acid inhibitor induces a novel conformational change in the active site ofInfluenza B virusneuraminidase. Acta Crystallographica Section D: Biological Crystallography, 2004, 60, 1017-1023.	2.5	4
40	Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: modifications of essential pyrrolidinone ring substituents. Bioorganic and Medicinal Chemistry, 2003, 11, 2739-2749.	1.4	28
41	Antibody Epitopes on the Neuraminidase of a Recent H3N2 Influenza Virus (A/Memphis/31/98). Journal of Virology, 2002, 76, 12274-12280.	1.5	90
42	Contacts between Influenza Virus N9 Neuraminidase and Monoclonal Antibody NC10. Virology, 2002, 300, 255-268.	1.1	20
43	Evaluation of influenza A virus receptors. International Congress Series, 2001, 1219, 487-502.	0.2	0
44	Apoptosis by influenza viruses correlates with efficiency of viral mRNA synthesis. Virus Research, 2001, 77, 3-17.	1.1	54
45	Influenza Neuraminidase as Target for Antivirals. Advances in Virus Research, 1999, 54, 375-402.	0.9	19
46	Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1901-1906.	1.0	32
47	Hydrophobic benzoic acids as inhibitors of influenza neuraminidase. Bioorganic and Medicinal Chemistry, 1999, 7, 2487-2497.	1.4	36
48	Influenza Type B Neuraminidase Can Replace the Function of Type A Neuraminidase. Virology, 1999, 264, 265-277.	1.1	11
49	Potent Inhibition of Influenza Sialidase by a Benzoic Acid Containing a 2-Pyrrolidinone Substituent. Journal of Medicinal Chemistry, 1999, 42, 2332-2343.	2.9	60
50	Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site 1 1Edited by I. A. Wilson. Journal of Molecular Biology, 1999, 293, 1107-1119.	2.0	61
51	Site-directed mutagenesis of catalytic residues of influenza virus neuraminidase as an aid to drug design. FEBS Journal, 1998, 258, 320-331.	0.2	50
52	Critical Interactions in Binding Antibody NC41 to Influenza N9 Neuraminidase:Â Amino Acid Contacts on the Antibody Heavy Chainâ€. Biochemistry, 1998, 37, 10660-10670.	1.2	12
53	Generation and Characterization of a Mutant of Influenza A Virus Selected with the Neuraminidase Inhibitor BCX-140. Antimicrobial Agents and Chemotherapy, 1998, 42, 801-807.	1.4	40
54	Hemagglutinin Specificity and Neuraminidase Coding Capacity of Neuraminidase-Deficient Influenza Viruses. Virology, 1997, 229, 155-165.	1.1	47

#	Article	IF	Citations
55	A strategy for theoretical binding constant,Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase. Proteins: Structure, Function and Bioinformatics, 1995, 23, 264-277.	1.5	45
56	Molecular Basis for the Resistance of Influenza Viruses to 4-Guanidino-Neu5Ac2en. Virology, 1995, 214, 642-646.	1.1	125
57	Probing the Structure of Influenza B Hemagglutinin Using Site-Directed Mutagenesis. Virology, 1995, 206, 787-795.	1.1	12
58	Red Cells Bound to Influenza Virus N9 Neuraminidase Are Not Released by the N9 Neuraminidase Activity. Virology, 1995, 211, 278-284.	1.1	28
59	Structure-Based Inhibitors of Influenza Virus Sialidase. A Benzoic Acid Lead with Novel Interaction. Journal of Medicinal Chemistry, 1995, 38, 3217-3225.	2.9	74
60	A Sialic Acid-derived Phosphonate Analog Inhibits Different Strains of Influenza Virus Neuraminidase with Different Efficiencies. Journal of Molecular Biology, 1995, 245, 623-634.	2.0	76
61	Structures of Aromatic Inhibitors of Influenza Virus Neuraminidase. Biochemistry, 1995, 34, 3144-3151.	1.2	101
62	Defining the Requirements for an Antibody Epitope on Influenza Virus Neuraminidase:. Journal of Molecular Biology, 1994, 235, 747-759.	2.0	8
63	Structure of Influenza Virus Neuraminidase B/Lee/40 Complexed with Sialic Acid and a Dehydro Analog at 1.8-.ANG. Resolution: Implications for the Catalytic Mechanism. Biochemistry, 1994, 33, 8172-8179.	1.2	98
64	Identification of critical contact residues in the NC41 epitope of a subtype N9 influenza virus neuraminidase. Proteins: Structure, Function and Bioinformatics, 1993, 15, 121-132.	1.5	61
65	Selection and Characterization of a Neuraminidase-Minus Mutant of Influenza Virus and Its Rescue by Cloned Neuraminidase Genes. Virology, 1993, 194, 403-407.	1.1	124
66	Three-dimensional Structure of Influenza A N9 Neuraminidase and Its Complex with the Inhibitor 2-Deoxy 2,3-Dehydro-N-Acetyl Neuraminic Acid. Journal of Molecular Biology, 1993, 232, 1069-1083.	2.0	146
67	Transfer of the hemagglutinin activity of influenza virus neuraminidase subtype N9 into an N2 neuraminidase background. Virology, 1991, 183, 496-504.	1.1	38
68	Antigenic, sequence, and crystal variation in influenza B neuraminidase. Virology, 1990, 177, 578-587.	1.1	43
69	New crystalline forms of neuraminidase of type B human influenza virus. Journal of Molecular Biology, 1990, 214, 639-640.	2.0	10
70	Epitopes on protein antigens: Misconceptions and realities. Cell, 1990, 61, 553-556.	13.5	550
71	Crystal Structures of Influenza Virus Neuraminidase Complexed with Monoclonal Antibody Fab Fragments. , 1990, , 49-60.		0
72	Sialic acid is cleaved from glycoconjugates at the cell surface when influenza virus neuraminidases are expressed from recombinant vaccinia viruses. Virology, 1989, 170, 346-351.	1.1	20

#	Article	IF	Citations
73	The neuraminidase of influenza virus. Proteins: Structure, Function and Bioinformatics, 1989, 6, 341-356.	1.5	286
74	Distribution of sequence differences in influenza N9 neuraminidase of tern and whale viruses and crystallization of the whale neuraminidase complexed with antibodies. Virology, 1987, 160, 346-354.	1.1	55
75	Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism. Biochemistry, 1987, 26, 5351-5358.	1.2	105
76	Effects of site-specific mutation on structure and activity of influenza virus B/Lee/40 neuraminidase. Virology, 1987, 156, 253-258.	1.1	18
77	Nucleotide and deduced amino acid sequence of the influenza neuraminidase genes of two equine serotypes. Virology, 1986, 155, 460-468.	1.1	15
78	Loss of enzyme activity in a site-directed mutant of influenza neuraminidase compared to expressed wild-type protein. Virology, 1986, 148, 74-83.	1.1	23
79	The Molecular Basis of Antigenic Variation in Influenza Virus. Advances in Virus Research, 1986, 31, 53-102.	0.9	41
80	Variation in the membrane-insertion and "stalk" sequences in eight subtypes of influenza type A virus neuraminidase. Biochemistry, 1982, 21, 4001-4007.	1.2	61
81	Antigenicity of influenza virus hemagglutinin following chemical modification. Virology, 1981, 111, 538-548.	1.1	5
82	CONSERVATION AND VARIATION IN INFLUENZA GENE SEQUENCES. , 1981, , 29-44.		4
83	Rapid DNA Sequence Analysi. CRC Critical Reviews in Biochemistry, 1979, 6, 1-33.	2.0	8
84	Nucleotide Sequence Coding for the N-Terminal Region of the Matrix Protein of Influenza Virus. FEBS Journal, 1979, 96, 363-372.	0.2	61
85	Nucleotide sequence coding for the â€œsignal peptideâ€•and N terminus of the hemagglutinin from an Asian (H2N2) strain of influenza virus. Virology, 1979, 97, 468-472.	1.1	145
86	DNA Sequencing of Viral Genomes. , 1979, , 205-292.		2
87	Amino acid sequences from the gene F(Capsid) protein of bacteriophage Ï†X174. Journal of Molecular Biology, 1976, 107, 433-443.	2.0	19
88	A correction to the sequence of the alpha chains of horse haemoglobin. Journal of Molecular Biology, 1976, 103, 675-677.	2.0	8
89	DNA-dependent RNA polymerase from the thermophilic bacteriumThermus aquaticus. FEBS Letters, 1974, 38, 277-281.	1.3	16
90	Correlation between a Coat Protein Amino-terminal Sequence and a Ribosome-binding DNA Sequence from Ï†X 174. Nature: New Biology, 1973, 241, 40-41.	4.5	13

#	Article	IF	Citations
91	The Glycobiology of Influenza Viruses. , 0, , 839-850.		1
92	Influenza Virus Antiviral Targets. , 0, , 187-207.		5